NCCN Guidelines for Hodgkin Lymphoma V.1.2020 – Web Teleconference 07/26/19 Guideline Page Panel Discussion/References Institution Vote and Request YES NO ABSTAIN ABSENT HODG-8 Based on a review of the data and discussion, the panel 1 13 2 12 External request: consensus was not to make changes to the current recommendation. Submission from Seattle Genetics, Inc. to consider updated data and new analyses relevant to the use of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) as front-line therapy for patients with stage III or IV classic Hodgkin lymphoma (cHL). HODG-B (3 of 4) Based on a review of the data and discussion, the panel 18 0 0 11 External request: consensus supported the use of brentuximab vedotin + nivolumab as a second- and subsequent-line treatment option for Submission from Seattle Genetics, Inc. to relapsed/refractory cHL. The category of evidence for this consider revising the category of evidence and recommendation was changed from category 2B to category 2A. consensus to a category 2A for the use of brentuximab vedotin in combination with nivolumab as a second-line treatment option for relapsed/refractory cHL. HODG-B (3 of 4) Based on the discussion, the panel consensus was to include 18 0 0 11 Internal request: GEMOX as a subsequent therapy option for relapsed/refractory cHL. This is a category 2A recommendation. Comment to consider the inclusion of gemcitabine + oxaliplatin (GEMOX) as a subsequent therapy option for relapsed/refractory cHL. NCCN Guidelines for Hodgkin Lymphoma V.1.2020 – Web Teleconference 07/26/19 Guideline Page Panel Discussion/References Institution Vote and Request YES NO ABSTAIN ABSENT HODG-B (3 of 4) Based on the discussion and noted reference, the panel 18 0 0 11 Internal request: consensus was to include bendamustine + carboplatin + etoposide as a subsequent therapy option for relapsed/refractory Comment to consider the inclusion of cHL. This is a category 2A recommendation. bendamustine + carboplatin + etoposide as a subsequent therapy option for Reference: relapsed/refractory cHL. Budde LE, Wu D, Martin DB, et al. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 2018;183:601-607. HODG-B (3 of 4) Based on the discussion the panel consensus supported the use 18 0 0 11 Internal request: of C-MOPP as a subsequent therapy option for relapsed/refractory cHL. The category of evidence for this Panel discussion to reassess the category of recommendation was changed from category 2B to category 2A. evidence of C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) as a subsequent therapy option for relapsed/refractory cHL. HODG-E (1 of 2) Based on the discussion and noted reference, the panel 18 0 0 11 Internal request: consensus was to include brentuximab vedotin followed by AVD as a primary therapy option for older adults (age >60) with stage Comment to consider including brentuximab I-II unfavorable cHL or stage III-IV cHL. This is a category 2A vedotin followed by AVD as a primary therapy recommendation. option for older adults (age >60) with cHL. Reference: Evens AM, Advani RH, Helenowski IB, et al. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol 2018;36:3015-3022. .